# EDGAR Filing Document

**Accession Number:** 0001510964
**File Stem:** 0000950170-25-081934
**Filing Date:** 2025-6
**Character Count:** 7197
**Document Hash:** 95100b0baa44c4f5a4983eb400001c11
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-081934.hdr.sgml**: 20250605

**ACCESSION NUMBER**: 0000950170-25-081934

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250327

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250605

**DATE AS OF CHANGE**: 20250604

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CV Sciences, Inc.
- **CENTRAL INDEX KEY:** 0001510964
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 800944970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54677
- **FILM NUMBER:** 251024799

**BUSINESS ADDRESS:**
- **STREET 1:** 9530 PADGETT STREET
- **STREET 2:** SUITE 107
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92126
- **BUSINESS PHONE:** 866-290-2157

**MAIL ADDRESS:**
- **STREET 1:** 9530 PADGETT STREET
- **STREET 2:** SUITE 107
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CannaVEST Corp.
- **DATE OF NAME CHANGE:** 20130205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Foreclosure Solutions, Inc.
- **DATE OF NAME CHANGE:** 20110124

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): June 2**, 2025

------

CV SCIENCES, INC.

**(Exact name of Registrant as Specified in Its Charter)** 

------

---

| | | |
|:---|:---|:---|
| Delaware | 000-54677 | 80-0944970 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 9530 Padgett Street, Suite 107<br>San Diego**,** California |  | 92126 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (**866**)** 290-2157

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On June 2, 2025, CV Sciences, Inc. (the "Company") held the 2025 Annual Meeting in a virtual format. At the close of business on April 4, 2025, the record date for the 2025 Annual Meeting, there were 184,263,663 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company.

At the 2025 Annual Meeting, 100,682,501 of the 184,263,663 outstanding shares of common stock entitled to vote, or approximately 54.6%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2025 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference.

The final voting results on the proposals presented for stockholder approval at the 2025 Annual Meeting were as follows:

**Proposal 1 - Election of Directors**

The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject to prior death, resignation or removal, as set forth below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **NAME** | **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTE** |
| Dr. Jamie Corroon | 17,035,995 | 2,022,683 | 16,914,582 | 64,709,241 |
| Joseph Dowling | 30,597,236 | 4,714,202 | 661,822 | 64,709,241 |
| Bill McCorkle | 32,887,813 | 2,101,673 | 983,774 | 64,709,241 |

---

**Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm**

The Company's stockholders ratified Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTE** |
| 92,535,025 | 6,882,600 | 1,264,876 | - |

---

**Proposal 3 - Advisory Vote to Approve Named Executive Officer Compensation**

The Company's stockholders approved, on a non-binding advisory basis, the Company's named executive officer compensation, as set forth below:

---

| | | | |
|:---|:---|:---|:---|
| **FOR** | **AGAINST** | **ABSTAIN** | **BROKER NON-VOTE** |
| 28,619,025 | 5,363,646 | 1,990,176 | 64,709,241 |

---

**Proposal 4 - Advisory Vote to as to Whether the Advisory Vote to Approve Named Executive Officer Compensation Should Take Place Every 1, 2 or 3 Years**

The Company's stockholders approved, on a non-binding advisory basis, that the frequency of the advisory, non-binding vote approving the named executive officer compensation shall take place every two (2) years, as set forth below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1 YEAR** | **2 YEARS** | **3 YEARS** | **ABSTAIN** | **BROKER NON-VOTE** |
| 5,077,976 | 27,373,437 | 1,988,116 | 1,533,731 | 64,709,241 |

---

------

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CV SCIENCES, INC.** | **CV SCIENCES, INC.** |
| Date: June 4, 2025 | By: | /s/ Joseph Dowling |
|  |  | Joseph Dowling |
|  |  | Chief Executive Officer |

---

------